Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
Chizuka A, Suda M, Shibata T, et al. Difference between hematological malignancy and solid tumor research articles published in four major medical journals. Leukemia. 2006;20:1655–7.
Avritscher EB, Cooksley CD, Rolston KV, et al. Serious postoperative infections following resection of common solid tumors: outcomes, costs, and impact of hospital surgical volume. Support Care Cancer. 2014;22:527–35.
Gudiol C, Aguado JM, Carratalà J. Bloodstream infections in patients with solid tumors. Virulence. 2016;7:298–308.
Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy. 2012;32:722–34.
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.
Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006;42:533–40.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–93.
Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–810.
Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis. 1999;29:515–21.
Virizuela JA, Carratalà J, Aguado JM, et al. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol. 2016;18:557–70.
Rolston KV, Mihu C, Tarrand JJ. Current microbiology of percutaneous endoscopic gastrostomy tube (PEG tube) insertion site infections in patients with cancer. Support Care Cancer. 2011;19:1267–71.
Abers MS, Sandvall BP, Sampath R, et al. Postobstructive pneumonia: an underdescribed syndrome. Clin Infect Dis. 2016;62:957–61.
Rolston KV. Postobstructive pneumonia in cancer patients. Clin Infect Dis. 2016;63:707–8.
Bin Nafisah S, Ahmad M. Ommaya reservoir infection rate: a 6-year retrospective cohort study of Ommaya reservoir in pediatrics. Childs Nerv Syst. 2015;31:29–36.
Bahu R, Chaftari AM, Hachem RY, et al. Nephrostomy tube related pyelonephritis in patients with cancer: epidemiology, infection rate and risk factors. J Urol. 2013;189:130–5.
Rolston KV, Nesher L, Tarrand JT. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect Dis Ther. 2014;3:245–56.
Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93:143–9.
Rolston KV. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol. 2001;13:218–23.
Badgwell BD, Cormier JN, Wray CJ, et al. Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg. 2008;248:104–9.
Yapici O, Gunseren F, Yapici H, Merdin A, Yaylali Ü, Merdin FA. Evaluation of febrile neutropenic episodes in adult patients with solid tumors. Mol Clin Oncol. 2016;4:379–82.
Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69:417–23.
Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005;51:215–8.
Torres A, Ferrer M. Editorial Commentary: Distinguishing postobstructive lung infection from community-acquired pneumonia. Clin Infect Dis. 2016;62:962–3.
Hsu-Kim C, Hoag JB, Cheng GS, Lund ME. The microbiology of postobstructive pneumonia in lung cancer patients. J Bronchol Interv Pulmonol. 2013;20:266–70.
Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.
Quint LE. Thoracic complications and emergencies in oncologic patients. Cancer Imaging. 2009;9(Spec No A):S75–82.
de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho HA. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12:471–8.
Barr SP, Topps AR, Barnes NL, et al. Infection prevention in breast implant surgery—a review of the surgical evidence, guidelines and a checklist. Eur J Surg Oncol. 2016;42:591–603.
Brand JS, Colzani E, Johansson AL, et al. Infection-related hospitalizations in breast cancer patients: risk and impact on prognosis. J Infect. 2016;72:650–8.
Quinn TT, Miller GS, Rostek M, Cabalag MS, Rozen WM, Hunter-Smith DJ. Prosthetic breast reconstruction: indications and update. Gland Surg. 2016;5:174–86.
Nahabedian MY, Tsangaris T, Momen B, Manson PN. Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg. 2003;112:467–76.
Cordeiro PG, McCarthy CM. A single surgeon’s 12-year experience with tissue expander/implant breast reconstruction: part II. An analysis of long-term complications, aesthetic outcomes, and patient satisfaction. Plast Reconstr Surg. 2006;118:832–9.
Francis SH, Ruberg RL, Stevenson KB, et al. Independent risk factors for infection in tissue expander breast reconstruction. Plast Reconstr Surg. 2009;124:1790–6.
Cordeiro PG, Pusic AL, Disa JJ, McCormick B, VanZee K. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg. 2004;113:877–81.
Epstein M, Silverstein M, Lin K, et al. Acute and chronic complications in breast cancer patients treated with intraoperative radiation therapy. Ann Surg Oncol. 2016;23:3304–9.
Huo J, Smith BD, Giordano SH, Reece GP, Shih YC. Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer. Breast Cancer Res Treat. 2016;157:373–83.
Seng P, Bayle S, Alliez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. Int J Infect Dis. 2015;35:62–6.
Rolston KV, Nesher L, Tarrand JT. Current microbiology of surgical site infections in patients with cancer: a retrospective review. Infect Dis Ther. 2014;3:245–256.
McCullough MC, Chu CK, Duggal CS, Losken A, Carlson GW. Antibiotic prophylaxis and resistance in surgical site infection after immediate tissue expander reconstruction of the breast. Ann Plast Surg. 2014;73:1–5.
Viola GM, Raad II, Rolston KV. Breast tissue expander-related infections: perioperative antimicrobial regimens. Infect Control Hosp Epidemiol. 2014;35:75–81.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Guideline for Prevention of Surgical Site Infection. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;1999(27):97–132.
Feldman EM, Kontoyiannis DP, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough? Plast Reconstr Surg. 2010;126:779–85.
Ariyan S, Martin J, Lal A, et al. Antibiotic prophylaxis for preventing surgical-site infection in plastic surgery: an evidence-based consensus conference statement from the American Association of Plastic Surgeons. Plast Reconstr Surg. 2015;135:1723–39.
Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? Plast Reconstr Surg. 2013;131:1–13.
Viola GM, Baumann DP, Mohan K, et al. Improving antimicrobial regimens for the treatment of breast tissue expander-related infections. Plast Reconstr Surg Glob Open. 2016;4:e704.
Viola GM, Selber JC, Crosby M, et al. Salvaging the infected breast tissue expander: a standardized multidisciplinary approach. Plast Reconstr Surg Glob Open. 2016;4:e732.
Cohen JB, Carroll C, Tenenbaum MM, Myckatyn TM. Breast implant-associated infections: the role of the national surgical quality improvement program and the local microbiome. Plast Reconstr Surg. 2015;136:921–9.
Weichman KE, Levine SM, Wilson SC, Choi M, Karp NS. Antibiotic selection for the treatment of infectious complications of implant-based breast reconstruction. Ann Plast Surg. 2013;71:140–3.
Huang SY, Philip A, Richter MD, Gupta S, Lessne ML, Kim CY. Prevention and management of infectious complications of percutaneous interventions. Semin Interv Radiol. 2015;32:78–88.
Shi S, Xia W, Guo H, Kong H, Zheng S. Unique characteristics of pyogenic liver abscesses of biliary origin. Surgery. 2016;159:1316–24.
Sun Z, Li G, Ai X, et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol. 2011;79:164–74.
Shin JU, Kim KM, Shin SW, et al. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Dig Liver Dis. 2014;46:813–7.
Rolston KV, Dholakia N, Rodriguez S, Rubenstein EB. Nature and outcome of febrile episodes in patients with pancreatic and hepatobiliary cancer. Support Care Cancer. 1995;3:414–7.
Xu C, Lv PH, Huang XE, Wang SX, Sun L, Wang FA. Analysis of different ways of drainage for obstructive jaundice caused by hilar cholangiocarcinoma. Asian Pac J Cancer Prev. 2014;15:5617–20.
Sugiyama G, Okabe Y, Ishida Y, et al. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma. World J Gastroenterol. 2014;20:6968–73.
Schneider J, Hapfelmeier A, Fremd J, et al. Biliary endoprosthesis: a prospective analysis of bacterial colonization and risk factors for sludge formation. PLoS ONE. 2014;9:e110112.
Fujii T, Yamada S, Suenaga M, et al. Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study. Pancreas. 2015;44:465–70.
Gorschlüter M, Marklein G, Höfling K, et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. Br J Haematol. 2002;117:351–8.
Capria S, Vitolo D, Cartoni C, et al. Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma. Ann Hematol. 2004;83:195–7.
Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56:711–7.
Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000;355:281–3.
Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. Lancet. 2000;355:2164.
de Matteis A, Nuzzo F, Rossi E, Landi G, Perrone F. Intestinal side-effects of docetaxel/vinorelbine combination. Lancet. 2000;355:1098–9.
Kirkpatrick ID, Greenberg HM. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology. 2003;226:668–74.
Cartoni C, Dragoni F, Micozzi A, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol. 2001;19:756–61.
Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693–703.
Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol. 1996;61:369–72.
Allen VA, Manahan KJ, Geisler JP. Recurrent pseudomembranous colitis in an ovarian cancer patient undergoing carboplatin chemotherapy. Case Rep Obstet Gynecol. 2016;2016:7540302.
Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:1776–81.
Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892–900.
Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015;26:305–12.
Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165:609–616.
Schlick K, Grundbichler M, Auberger J, et al. Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infect Agent Cancer. 2015;10:45.
Torres HA, Kontoyiannis DP, Bodey GP, et al. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer. 2005;41:2268–79.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–9.
Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202:192–201.
Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55(Suppl 1):S10–5.
Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212–20.
Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33:167–77.
Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.
Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.
Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346–52.
Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999–3008.
Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14:882–913.
Torres HA, Mahale P, Blechacz B, et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Cancer Netw. 2015;13:41–50.
Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.
Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol. 2014;20:2771–6.
Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270–80.
Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716–24.
Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387–92.
Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56:1646–53.
Flukes S, Hayne D, Kuan M, Wallace M, McMillan K, Rukin NJ. Retrograde ureteric stent insertion in the management of infected obstructed kidneys. BJU Int. 2015;115(Suppl 5):31–4.
Benson AD, Taylor ER, Schwartz BF. Metal ureteral stent for benign and malignant ureteral obstruction. J Urol. 2011;185:2217–22.
Goldsmith ZG, Wang AJ, Bañez LL, et al. Outcomes of metallic stents for malignant ureteral obstruction. J Urol. 2012;188:851–5.
de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v252–6.